ImmunityBio (IBRX) revenue

Revenue · fiscal 2025
$113.29M

ImmunityBio (IBRX) reported revenue of $113.29M in fiscal 2025 (the year ended December 31, 2025). That is 668.3% higher than the $14.75M of fiscal 2024. Figures as of 18 Nov 2026, 09:28 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$113.29M
Change on fiscal 2024
+668.3%
Growth, 5 years
+184.8% a year
Growth, 10 years
+85.4% a year
Highest on record
$113.29Mfiscal 2025
Lowest on record
$44.00Kfiscal 2016
Fiscal years on record
132013–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

ImmunityBio revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 184.8% a year; over ten years the rate was 85.4% a year. Across the 13 fiscal years on record (2013–2025), the highest was $113.29M in fiscal 2025 and the lowest $44.00K in fiscal 2016.

History · 13 fiscal years

Revenue by fiscal year

ImmunityBio revenue, year by year

ImmunityBio (IBRX) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$113.29M 668.3% up
2024$14.75M 2,270.6% up
2023$622.00K 159.2% up
2022$240.00K 74.3% down
2021$934.00K 54.4% up
2020$605.00K 72.5% down
2019$2.20M 4,585.1% up
2018$47.00K 4.4% up
2017$45.00K 2.3% up
2016$44.00K 81.4% down
2015$236.00K 63.2% down
2014$641.00K 6.8% up
2013$600.00K—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of ImmunityBio and comparable companies
CompanyRevenueFiscal year
Alkermes ALKS$1.48B2025
PACS Group PACS$5.29B2025
Kiniksa Pharmaceuticals International KNSA$677.56M2025
ImmunityBio IBRX$113.29M2025
Cytokinetics CYTK$88.04M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on IBRX

ImmunityBio, figure by figure

ImmunityBio (IBRX) overview: price, valuation and scorecardAll health care companies by market value

ImmunityBio revenue: questions and answers

What is ImmunityBio's revenue?

ImmunityBio (IBRX) reported revenue of $113.29M in fiscal 2025 (the year ended December 31, 2025). That is 668.3% higher than the $14.75M of fiscal 2024.

What is the growth rate of ImmunityBio's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 184.8% a year; over ten years the rate was 85.4% a year.

What are the highest and lowest revenue figures on record for ImmunityBio?

Across the 13 fiscal years on record (2013–2025), the highest was $113.29M in fiscal 2025 and the lowest $44.00K in fiscal 2016.

How is ImmunityBio's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For ImmunityBio it is on record here for 13 fiscal years, 2013 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “ImmunityBio (IBRX) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/IBRX/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.